Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
non-Hodgkin lymphoma
Biotech
ASH: Should existing BTKs worry about Lilly's newcomer?
The three existing BTK inhibitors can't be used in patients who've failed one another. But Lilly's pirtobrutinib shows it can.
Angus Liu
Dec 12, 2022 5:30pm
FDA feedback drives MEI, Kyowa to halt blood cancer program
Dec 6, 2022 7:18am
MEI, Kyowa confirm phase 2 cancer efficacy with fresh data drop
Nov 18, 2022 9:35am
In a first, Allogene starts pivotal off-the-shelf CAR-T trial
Oct 7, 2022 6:00am
Caribou's CAR-T hit by durability doubts as patients relapse
Jun 10, 2022 8:06am
Precision hails early data of its ‘off-the-shelf’ CAR-T therapy
Jun 8, 2022 10:25am
